Ultrasensitive detection of αSynD in clinically accessible biospecimens from living synucleinopathy patients, such as cerebrospinal fluid (CSF) and peripheral tissues has further boosted the diagnostic utility of SAAs [18,41–43]. This evidence concerns the gene PCSK1N and synucleinopathy.